Skip to main content
. 2018 Oct 15;5:25. doi: 10.1186/s40658-018-0224-9

Table 6.

Inter-observer variability of dosimetry estimates in 60 induction cycles received by 15 patients

Relative error (%)
Kidney Bone marrowtotal Tumormax
Observer 2 vs. observer 1
 Per cycle
  3TP − 0.2 ± 3.4 (− 7.8–10.0) − 2.4 ± 20.4 (− 53.7–75.9) − 0.2 ± 8.6 (− 34.1–40.5)
  2TP − 0.3 ± 3.4 (− 9.0–8.2) − 2.2 ± 20.9 (− 50.9–7.8) − 0.2 ± 8.2 (− 33.0–38.4)
  2TP/1TPD3 − 0.5 ± 3.4 (− 8.8–7.8) − 11.2 ± 25.5 (− 98.2–30.6) −1.9 ± 6.2 (− 33.0–6.4)
 Cumulative
  3TP − 0.2 ± 2.3 (− 2.9–3.9) − 4.5 ± 8.9 (− 24.0–7.8) − 0.6 ± 4.0 (− 8.3–8.0)
  2TP − 0.3 ± 2.3 (− 4.2–3.6) − 4.4 ± 8.8 (− 21.5–8.0) − 0.6 ± 3.8 (− 7.8–7.1)
  2TP/1TPD3 − 0.5 ± 2.3 (− 3.9–4.0) − 12.1 ± 19.7 (− 68.5–11.4) − 6.1 ± 10.1 (− 32.2–4.5)
Observer 3 vs. observer 1
 Per cycle
  3TP − 0.5 ± 4.7 (− 21.5–9.4) 3.6 ± 29.0 (− 31.2–153.2) − 4.6 ± 9.0 (− 42.2–14.2)
  2TP − 0.3 ± 4.5 (− 21.4–8.2) 4.2 ± 29.9 (− 33.5–159.3) − 4.3 ± 8.7 (− 39.9–13.5)
  2TP/1TPD3 − 0.7 ± 5.8 (− 35.7–9.4) − 16.3 ± 35.9 (− 98.0–57.9) − 2.9 ± 8.6 (− 39.9–15.0)
 Cumulative
  3TP − 0.4 ± 1.5 (− 2.6–3.5) 1.9 ± 12.0 (− 13.2–31.4) − 3.9 ± 5.2 (− 11.0–10.7)
  2TP − 0.2 ± 1.2 (− 1.6–3.3) 2.3 ± 12.3 (− 13.7–31.9) − 3.7 ± 5.0 (− 10.7–10.1)
  2TP/1TPD3 − 0.6 ± 2.8 (− 9.5–3.9) − 17.3 ± 25.8 (− 74.7–3.3) − 5.5 ± 11.0 (− 33.8–13.5)
Observer 3 vs. observer 2
 Per cycle
  3TP − 0.2 ± 5.1 (− 24.0–13.1) 7.3 ± 23.2 (− 30.0–82.2) − 4.1 ± 9.4 (− 28.4–25.2)
  2TP 0.0 ± 4.8 (− 22.6–10.0) 7.8 ± 23.9 (− 29.8–92.5) − 3.8 ± 9.1 (− 27.5–23.6)
  2TP/1TPD3 − 0.2 ± 6.4 (− 38.4–10.3) − 3.7 ± 33.9 (− 93.0–92.5) − 0.9 ± 7.4 (− 14.8–24.0)
 Cumulative
  3TP − 0.2 ± 2.0 (− 3.6–3.0) 7.0 ± 11.4 (− 7.9–34.3) − 3.2 ± 7.8 (− 17.5–20.7)
  2TP 0.1 ± 2.2 (− 3.9–3.6) 7.2 ± 11.0 (− 8.6–29.2) − 2.9 ± 7.4 (− 16.6–19.4)
  2TP/1TPD3 − 0.1 ± 3.4 (− 10.3–3.3) − 4.4 ± 25.6 (− 68.2–27.9) 1.0 ± 10.4 (− 8.0–27.8)

D3 day 3, TP time point(s)`

Data is presented as mean ± SD (range)